Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Eric Jay Small, Jack Youngren, George Thomas, Susan Olson, Alexandria Toschi, Adam Foye, Joshi J. Alumkal, Matthew Rettig, Martin Edwin Gleave, Christopher P. Evans, Josh Stuart, Charles J. Ryan, Robert Evan Reiter, Kim N. Chi, Primo Lara, Tomasz M. Beer, PCF/SU2C/AACR West Coast Prostate Cancer Dream Team
Institutions: University of California, San Francisco, OHSU Knight Cancer Institute, Oregon Health & Science University, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Vancouver Prostate Centre, University of California, Davis, University of California, Santa Cruz, BC Cancer Agency, University of California Davis Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2509725628